TrkB-Targeted Therapy for Mucoepidermoid Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• The brain-derived neurotrophic factor (BDNF)/tyrosine receptor kinase B (TrkB) pathway is implicated in adenocarcinoma oncogenesis.
• The role of the BDNF/TrkB pathway in mucoepidermoid carcinoma (MEC) remains underexplored.

Purpose of the Study:

• To investigate the role of the BDNF/TrkB pathway in MEC.
• To evaluate the efficacy of TrkB inhibition, alone and in combination with Cisplatin, on MEC cell behavior.

Main Methods:

• Utilized three MEC cell lines (UM-HMC-2, H253, H292).
• Treated cells with Cisplatin, the TrkB inhibitor ANA-12, or a combination.
• Assessed ultrastructural changes via transmission electron microscopy.
• Evaluated migration and invasion using scratch and Transwell assays.
• Determined survival and cancer stem cell (CSC) percentage via clonogenic and spheroid-forming assays.

Main Results:

• Cisplatin induced significant cytotoxicity and reduced CSCs.
• ANA-12 demonstrated less pronounced cytotoxicity but reduced CSCs.
• Both drugs individually and in combination delayed MEC cell migration, invasion, and survival.
• Combination therapy showed less reduction in CSCs compared to Cisplatin alone, with subsequent recovery of spheroid-forming capacity.

Conclusions:

• TrkB inhibition effectively impairs MEC cell migration, invasion, and survival in vitro.
• The combined treatment's limited efficacy in reducing CSCs compared to Cisplatin alone is a significant limitation.
• Further research is needed to optimize combination therapies for MEC treatment targeting the BDNF/TrkB pathway.